Download the Visual
In payor-managed indications, the indication a biotech picks sets its commercial strategy
Even a best-in-class drug can stall at launch in a payor-managed (or payer-managed) indication, because the incentives of pharmacy benefit managers (PBMs) and other intermediaries favor incumbents. In an illustrative case from Sleuth’s November 2024 framework, a new entrant with a tenth of an incumbent’s patients, at the same price, generates less rebate for a PBM at a 75% discount than the incumbent does at 10%. The indication a biotech picks dictates its commercial strategy, and most teams underestimate it.
In late 2024, Sleuth expected more biotechs to launch drugs themselves, given the number of companies and a slowdown in buyouts.
Three factors push an indication toward heavy payor management
Payor management is a sliding scale. An indication sits further toward the managed end when it has high spending, usually from a large patient population; many competitors, especially pharma companies with broad portfolios; and a disease that is not immediately deadly.
On Sleuth’s scale, I&I, cardiovascular and metabolic indications such as IBD, rheumatoid arthritis, diabetes, cholesterol and weight loss are the most managed. Asthma and COPD, neuropsychiatric disorders, infectious disease, hematology and IV oncology follow in turn, with rare disease the least managed.
The closer a drug sits to the managed end, the more its launch depends on working the US drug pricing system rather than on clinical data alone.
Rebate math favors incumbent volume over bigger discounts
PBMs and payors earn rebates tied to a drug’s price, the percentage discount and prescription volume. In Sleuth’s illustration, an incumbent with 10,000 patients at a $1,000 monthly price and a 10% discount generates a $1 million rebate, while a new entrant with 1,000 patients at the same price and a 75% discount generates $750,000. The PBM still earns more from the incumbent, which helps explain why Humira biosimilars were slow to take share despite list-price (WAC) discounts of more than 80%.
Two forces compound the effect. Physicians and patients are reluctant to switch from drugs that work, so plans struggle to move existing patients to a new entrant unless they are refractory. Big pharma can also use bundled contracting, rebating across a portfolio in exchange for preferential treatment. That works between pharma companies too: in 2024, AbbVie’s I&I portfolio gave it more leverage than Lilly’s.
Federal PBM reform, only proposed when Sleuth published this framework, became law in February 2026 but does not start until 2028, when Medicare Part D PBM fees must stop depending on drug prices or rebates, and 2029, when PBMs must pass all rebates through to employer health plans.
A biotech that proves clinical superiority can still struggle at launch, because these incentives steer payors toward existing drugs through step therapy, formulary tiering and prior authorization.
First movers turn early lock-in into a reinvestment loop
In managed indications, early lock-in with patients, physicians and payors wins market share, which brings more data, cross-product opportunities and brand awareness. Winners reinvest in indication expansion, marketing and new launches, strengthening their bundled contracting offer. The same dynamic helps explain why biopharma markets converge on duopolies.
Timing and portfolio fit can matter as much as efficacy in managed indications, while less-managed areas such as rare disease and IV oncology reward clinical differentiation more directly.
The framework and rebate example are from Sleuth’s November 2024 cheat sheet; the rebate figures are illustrative, not market data. PBM reform details are as of February 2026.
Frequently asked questions about payor-managed indications
What is a payor-managed indication?
An indication where payors and PBMs actively control access through rebates, step therapy, formulary tiering and prior authorization. In Sleuth’s November 2024 framework, the markers are high spending, many competitors (especially pharma) and a disease that is not immediately deadly; I&I, cardiovascular and metabolic indications are the most managed and rare disease the least.
Why doesn’t a bigger discount win a new drug formulary access?
Because rebates scale with volume. In Sleuth’s 2024 example, an incumbent with 10,000 patients at a 10% discount yields a $1 million rebate, while a new entrant with 1,000 patients at a 75% discount yields $750,000, so the PBM earns more by favoring the incumbent.
Has PBM reform changed these incentives?
Not yet. The Consolidated Appropriations Act, 2026, signed in February 2026, delinks PBM fees from drug prices in Medicare Part D from January 2028 and requires full rebate pass-through to employer health plans from January 2029.
